文章:
副肿瘤神经变性:肿瘤免疫的关键
Paraneoplastic neurological degenerations: keys to tumour immunity
原文发布日期:2004-01-01
DOI: 10.1038/nrc1255
类型: Review Article
开放获取: 否
要点:
- The study of paraneoplastic neurological degenerations (PNDs) provides a means to observe naturally occurring, successful human antitumour immune responses.
- PND antigens, which are identified using antisera from patients with PNDs to screen expression complementary DNA libraries, can be used to study the specific nature of the associated antitumour immune response.
- The PND tumour immune response is characterized by the presence of PND antigen-specific CD8+ killer T cells in the blood of patients.
- An important trigger of PND antigen-specific CD8+ killer T cells in patients with cancer is likely to be the capture of apoptotic tumour cells by tissue dendritic cells, which then migrate to the lymph node to activate T cells.
- The activation of CD8+ killer T cells in the lymph node appears to depend on the presence of CD4+ helper T cells; in their absence, CD8+ T cells might become tolerized.
要点翻译:
- 对副肿瘤性神经退行性病变(PNDs)的研究为观察自然发生的、成功的人类抗肿瘤免疫反应提供了途径。
- 通过使用PND患者抗血清筛选表达互补DNA文库而鉴定出的PND抗原,可用于研究相关抗肿瘤免疫反应的具体特性。
- PND肿瘤免疫反应的特征在于患者血液中存在PND抗原特异性CD8+杀伤性T细胞。
- 癌症患者中PND抗原特异性CD8+杀伤性T细胞的重要触发因素可能是组织树突状细胞捕获凋亡肿瘤细胞,随后迁移至淋巴结激活T细胞。
- 淋巴结中CD8+杀伤性T细胞的激活似乎依赖于CD4+辅助性T细胞的存在;若缺乏CD4+ T细胞,CD8+ T细胞可能会产生免疫耐受。
英文摘要:
Paraneoplastic neurological degenerations (PNDs) are neurological disorders that develop in patients with cancer. PNDs are triggered by an effective antitumour immune response against neuronal antigens that are expressed in cancer cells, which subsequently develops into autoimmune neurodegenerative disease. Studying patients with PND has offered the opportunity to gain unique insights into mechanisms of tumour immunity and has provided the potential to apply this knowledge to patients with cancer in general.
摘要翻译:
副肿瘤性神经系统变性(PNDs)是发生在癌症患者中的一类神经系统疾病。PNDs 是由针对癌细胞中表达的神经元抗原的有效抗肿瘤免疫反应引发的,随后发展为自身免疫性神经退行性疾病。对 PND 患者的研究为了解肿瘤免疫机制提供了独特的机会,并为将这些知识应用于普通癌症患者提供了可能性。
原文链接:
Paraneoplastic neurological degenerations: keys to tumour immunity